A new linker lowered kidney radiation in mice, but the treatment did not work better
Original title: Reducing renal radioactivity of radiolabeled tetravalent RGD peptides via cleavable linkers for targeted radionuclide therapy.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done in animals, not people. Most findings at this stage never become treatments.
This was only done in mice, and the change they tested did not work better.
The short version
Researchers tried to protect the kidneys during a radiation-carrying drug treatment, and the change did not improve the result in mice.
What was studied. Scientists tested a drug that carries radiation and is designed to stick to tumors. They added two kinds of breakable links, called GK and GD, to help the body clear radiation out of the kidneys faster. They tested it in mice that had human glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary tumors.
What they found. Both new versions left less radiation in the kidneys than the original version. But they also left less radiation in the tumor. So the balance between tumor and kidney stayed the same as before. The team found that the links were being broken inside tumor cells, in a part of the cell that breaks things down.
What this means, and what it doesn't
What it could mean: For now, this does not change care for anyone. It is early lab work in mice. It tells researchers that this way of protecting the kidneys also weakens the drug's hold on the tumor, so they will need another approach.
What it doesn't mean: This is not a new treatment. It was done in mice, not in people. It was not tested for safety or benefit in humans, and there is no trial you can join based on this work. The change they tested did not even improve results in the mice. This is not a cure, and it is many steps away from anything a doctor could offer you.
Source: PubMed, August 6, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.